APOL3 and neoplasm: Consistent with above findings, tumor volume analysis indicated that APOL3-OE of CT26 with treatment of RSL3 significantly increased the antitumor ability of PD-1 inhibitor in vivo and this effect can be diminished by co-overexpression of LDHA (Figure 6B).